Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35210874 | 0.84 | SMN1; SMN2 (0.57) | MAPK14PTGER1MEN1KMT2ABRD9 | |
| SCHEMBL19271750 | 0.83 | MAPK14 (0.47) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL2175532 | 0.83 | MAPK14 (0.47) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL19300006 | 0.83 | MAPK14 (0.47) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL25408156 | 0.81 | MAPK14 (0.46) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL21597704 | 0.81 | MAPK14 (0.46) | MAPK14MAPTLMNAATRBRD9 | |
| SCHEMBL21597716 | 0.81 | MAPK14 (0.46) | MAPK14ATRPTGER1CNR2BRD9 | |
| SCHEMBL25407400 | 0.80 | MAPK14 (0.46) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL25401903 | 0.79 | MAPK14 (0.45) | MAPK14MAPTLMNACNR2KMT2A | |
| SCHEMBL28617347 | 0.79 | MAPK14 (0.42) | MAPK14MAPTLMNAMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2516437-B1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| WO-2011076744-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | CYP4F2, CYP11B2, CYP4F3 | MAPK14 1963/4885MAPT 1194/4885LMNA 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.